NuvaRing® is not a daily pill. It’s a small, comfortable vaginal
ring. NuvaRing® delivers a continuous low dose of hormones.
When used as directed, it’s as e;ective as the pill, but you
don’t have to take it every day. In a given 1-month period, NuvaRing® must be
inserted, removed after 3 weeks, and a new ring must be inserted no more
than 7 days later. In a clinical trial, nine out of ten women who used NuvaRing®
would recommend it to others.
Ask your doctor if prescription NuvaRing® is right for
you, or for more information visit www.nuvaring.com.
Copyright © 2010 N.V. Organon, a subsidiary of Merck & Co., Inc.
All rights reserved. Printed in USA. NV0252 5/10
NuvaRing® is approved for the prevention of pregnancy in women.
IMPORTANT SAFETY INFORMATION
• The use of combination oral contraceptives is associated with increased risks of several serious side e;ects, including blood clots, which may
lead to stroke or heart attack. NuvaRing® is not for women with a history of these conditions. The risk of getting blood clots may be greater
with the type of progestin in NuvaRing® than with some other progestins in certain low-dose birth control pills. It is unknown if the risk of
blood clots is di;erent with NuvaRing® use than with the use of certain birth control pills.
• Cigarette smoking increases the risk of serious cardiovascular side e;ects when you use combination oral contraceptives.
This risk increases even more if you are over age 35 and if you smoke 15 or more cigarettes a day. Women who use
combination hormonal contraceptives, including NuvaRing®, are strongly advised not to smoke.
• NuvaRing® is not for women with certain cancers or those who may be pregnant.
• NuvaRing® does not protect against HIV infection and other sexually transmitted diseases.
• The most common side e;ects reported by NuvaRing® users are: vaginal infections and irritation, vaginal secretion, headache,
weight gain, and nausea.
Please see next page for additional important patient information.
You are encouraged to report negative side e;ects of
prescription drugs to the FDA.
